Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pieris Pharmaceuticals Inc (PIRS)

Pieris Pharmaceuticals Inc (PIRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,314
  • Shares Outstanding, K 1,320
  • Annual Sales, $ 42,810 K
  • Annual Income, $ -24,540 K
  • 60-Month Beta 0.68
  • Price/Sales 0.30
  • Price/Cash Flow N/A
  • Price/Book 0.55
Trade PIRS with:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 61.37%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,276.81% on 04/04/24
  • IV Low 0.00% on 07/02/24
  • Put/Call Vol Ratio 999.99
  • Today's Volume 36
  • Volume Avg (30-Day) 30
  • Put/Call OI Ratio 0.64
  • Today's Open Interest 128
  • Open Int (30-Day) 95

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year 4.00
  • Growth Rate Est. (year over year) +24,875.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.31 +4.40%
on 06/24/24
10.83 -19.85%
on 06/11/24
-1.52 (-14.90%)
since 06/03/24
3-Month
8.31 +4.40%
on 06/24/24
15.20 -42.89%
on 04/09/24
-5.26 (-37.72%)
since 04/03/24
52-Week
8.31 +4.40%
on 06/24/24
41.78 -79.23%
on 08/24/23
-4.95 (-36.33%)
since 07/03/23

Most Recent Stories

More News
Pieris Pharmaceuticals: Q1 Earnings Snapshot

Pieris Pharmaceuticals: Q1 Earnings Snapshot

PIRS : 8.68 (+1.28%)
Pieris Pharmaceuticals: Q3 Earnings Snapshot

Pieris Pharmaceuticals: Q3 Earnings Snapshot

PIRS : 8.68 (+1.28%)
Pieris Pharmaceuticals: Q1 Earnings Snapshot

Pieris Pharmaceuticals: Q1 Earnings Snapshot

PIRS : 8.68 (+1.28%)
Pieris Pharmaceuticals: Q3 Earnings Snapshot

Pieris Pharmaceuticals: Q3 Earnings Snapshot

PIRS : 8.68 (+1.28%)
Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference

BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

PIRS : 8.68 (+1.28%)
Chau Khuong Joins Catalio Capital Management as General Partner

Catalio Capital Management, LP (“Catalio”), a leading multi-strategy life sciences investment firm, today announced that Chau Khuong, who was most recently a Partner at OrbiMed Advisors, has joined...

FUSN : 21.55 (+0.14%)
GKOS : 119.29 (+0.26%)
NTLA : 22.95 (+3.61%)
ICPT : 19.00 (+0.21%)
INSP : 133.94 (-0.23%)
NXTC : 1.5700 (+4.67%)
PIRS : 8.68 (+1.28%)
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference

BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology...

PIRS : 8.68 (+1.28%)
Pieris Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDT BOSTON, MA / ACCESSWIRE / May 11, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology...

PIRS : 8.68 (+1.28%)
Pieris Pharmaceuticals To Host First Quarter 2022 Investor Call and Provide Corporate Update on May 11, 2022

Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.

PIRS : 8.68 (+1.28%)
3 Risky Stocks With Huge Potential Upside

Why risk-tolerant investors want to own Shopify, Silvergate Capital, and Pieris Pharmaceuticals.

PIRS : 8.68 (+1.28%)
SI : 1.2500 (+0.81%)
SHOP : 66.73 (+1.01%)
AMZN : 197.59 (-1.21%)
NVAX : 12.55 (-3.24%)
AZN : 76.80 (-0.25%)
SGEN : 228.74 (-0.07%)

Business Summary

Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.

See More

Key Turning Points

3rd Resistance Point 8.94
2nd Resistance Point 8.89
1st Resistance Point 8.78
Last Price 8.68
1st Support Level 8.63
2nd Support Level 8.58
3rd Support Level 8.47

See More

52-Week High 41.78
Fibonacci 61.8% 29.00
Fibonacci 50% 25.05
Fibonacci 38.2% 21.10
Last Price 8.68
52-Week Low 8.31

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar